Breaking Finance News

Peel Hunt announced BTG PLC (LON:BTG), renewing its target at 680.00GBX earlier today

Stating a potential downside of -0.02%, Peel Hunt hold steady the stock price target of BTG PLC (LON:BTG) at 680.00GBX

Just yesterday BTG PLC (LON:BTG) traded -0.07% lower at 694.50GBX. BTG’s 50-day average is 703.19GBX and its two hundred day average is 679.77GBX. With the last close up 10.48% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the date range. Trading volume was down over the average, with 347,453 shares of BTG changing hands under the typical 484,405

Recent Performance Chart


BTG PLC has a 52 week low of 528.36GBX and a 52 week high of 764.58GBX with a P/E ratio of 87.33 BTG PLC’s market capitalization is currently 0 GBX.

General Information About BTG PLC (LON:BTG)

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.